Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 01 June, 2011 and appeared in  MedicationType 2 DiabetesIssue 576GLP-1 Series Issue 1GLP-1 Series Issue 3GLP-1 Series Issue 4GLP-1 Series Issue 5GLP-1

Sanofi's Once Daily GLP-1 Lyxumia ® Meets Primary Endpoint in Phase 3 Study

Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia....

Advertisement

Sanofi announced that its GetGoal-L is one of nine studies in the GetGoal phase III clinical program, and the second trial to investigate the benefits of lixisenatide 20µg once-daily combined with basal insulin. It was a randomized (double-blind), placebo-controlled study with a 24-week main treatment period, and a total of 495 patients received either lixisenatide or placebo.

GetGoal-L showed a significant reduction in HbA1c levels (p=0.0002) with lixisenatide, without a significant increase in the incidence of symptomatic hypoglycemia (p=0.14) versus placebo. In addition, patients treated with lixisenatide had significantly improved postprandial plasma glucose after a test meal (p<0.0001). Patients in the lixisenatide arm of the study also reported a significant reduction in body weight (p<0.0001). These results confirm those previously reported on GetGoal-L Asia, this time in a broader population including both Caucasian and Asian patients. As expected with a GLP-1, the most commonly reported adverse event with lixisenatide was nausea with a low rate of discontinuation.

"These positive efficacy and safety results are another important milestone in the GetGoal clinical trial program and show the potential value of adding Lyxumia (lixisenatide) to basal insulin to improve glycemic control," said Pierre Chancel, senior vice president, Global Diabetes Division at Sanofi. "The findings from this and previous studies reinforce a continuing positive trend demonstrating the potential of lixisenatide to improve the lives of people with type 2 diabetes."

The full study results from GetGoal-L are planned to be presented at a medical congress.

Lixisenatide, a Glucagon-Like Peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus. Lixisenatide was in-licensed from Zealand Pharma A/S (Copenhagen, Denmark).

The GetGoal phase III clinical program will provide data for the efficacy and safety of lixisenatide in adults with type 2 diabetes treated with various oral anti-diabetic agents or insulin. With nine trials in the program, GetGoal started in May 2008 and has enrolled more than 4300 patients. To date GetGoal-X, GetGoal-Mono, GetGoal-L Asia and GetGoal-S have reported positive top-line results supporting efficacy and safety for lixisenatide. Further results are expected during 2011.

Sanofi News Release June, 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 01 June, 2011 and appeared in  MedicationType 2 DiabetesIssue 576GLP-1 Series Issue 1GLP-1 Series Issue 3GLP-1 Series Issue 4GLP-1 Series Issue 5GLP-1

Past five issues: SGLT-2 Inhibitors Special Edition April 2014 | Diabetes Clinical Mastery Series Issue 184 | Issue 724 | Diabetes Clinical Mastery Series Issue 183 | Issue 723 |

2014 Most Popular Articles:

Patient Handout: 7 Tips to Drop Excess Pounds with Diabetes
Posted April 04, 2014
Who Qualifies for Statin Treatment under the New Guidelines?
Posted March 27, 2014
Vitamin D's Effect on the Progression of Pre-type 1 Diabetes
Posted March 14, 2014
Updated Bolus Calculators for Diabetes Management
Posted March 20, 2014
Surprising Trends in the Use of Antidiabetic Drugs
Posted March 27, 2014
A1C Is a Predictor of Clinical Outcomes Following Noncardiac Surgery
Posted March 14, 2014
Abdominal Fat Accumulation Prevented by Unsaturated Fat
Posted March 14, 2014
Agavins: A Potential Alternative to Artificial Sweeteners
Posted March 27, 2014
Evidence Shows Possible Benefit of Metformin and Glyburide Use in Pregnancy
Posted March 14, 2014
GLP-1 Agonist Interaction with Insulin-Induced Hypoglycemia
Posted March 27, 2014

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
Cast Your Vote
Was the data release from CMS on Medicare payments a good idea?
CME/CE of the Week
Category: Nutrition
CE Credits: .5



Search Articles On Diabetes In Control